Documents
-
- Download
- Title Pages_Contents
-
open access
-
- Download
- Chapter 2
-
open access
- Full text at publishers site
-
- Download
- Chapter 3
-
open access
- Full text at publishers site
-
- Download
- Chapter 4
-
open access
- Full text at publishers site
-
- Download
- Appendices
-
open access
-
- Download
- Summary in Dutch
-
open access
-
- Download
- Propositions
-
open access
In Collections
This item can be found in the following collections:
Caging ruthenium complexes with non-toxic ligands for photoactivated chemotherapy
The main goal of the research described in this thesis was the development of new photoactivated chemotherapy (PACT) ruthenium(II) complexes bearing a non-toxic photolabile ligand. We first investigated whether non-toxic ligands such as L-proline, 2-(methylthio)methylpyridine (mtmp), or 3-(methylthio)propylamine (mtpa), once coordinated to ruthenium(II) complexes, could be photosubstituted upon visible light irradiation. The lipophilicity, and in some cases the strain of the ruthenium(II) complexes, were systematically varied and the effects of such variations on the cytotoxicity of the complexes in the dark and under light irradiation were studied. In the second part, the best ligand candidates (i.e. mtmp and mtpa) were coordinated to cyclometalated ruthenium complexes of the type [Ru(bpy)(phpy)(S,N)]PF6 (bpy = 2,2’-bipyridine and phpy = 2-phenylpyridine), to shift the absorption of the complex to the red region of the spectrum...
Show moreThe main goal of the research described in this thesis was the development of new photoactivated chemotherapy (PACT) ruthenium(II) complexes bearing a non-toxic photolabile ligand. We first investigated whether non-toxic ligands such as L-proline, 2-(methylthio)methylpyridine (mtmp), or 3-(methylthio)propylamine (mtpa), once coordinated to ruthenium(II) complexes, could be photosubstituted upon visible light irradiation. The lipophilicity, and in some cases the strain of the ruthenium(II) complexes, were systematically varied and the effects of such variations on the cytotoxicity of the complexes in the dark and under light irradiation were studied. In the second part, the best ligand candidates (i.e. mtmp and mtpa) were coordinated to cyclometalated ruthenium complexes of the type [Ru(bpy)(phpy)(S,N)]PF6 (bpy = 2,2’-bipyridine and phpy = 2-phenylpyridine), to shift the absorption of the complex to the red region of the spectrum. The photosubstitution properties of these cyclometallated complexes were investigated in detail. The most promising ruthenium complexes were tested in cancer cell monolayers under hypoxic conditions (1% O2) to investigate their mode of action and distinguish between PACT and PDT.
Show less- All authors
- Cuello Garibo, J.A.
- Supervisor
- Bouwman, E.
- Co-supervisor
- Bonnet, S.
- Committee
- Overkleeft, H.S.; Brouwer, J.; Alessio, E.; Keyes, T.E.
- Qualification
- Doctor (dr.)
- Awarding Institution
- Institute of Chemistry , Science , Leiden University
- Date
- 2017-12-19
- ISBN (print)
- 9789462997967